ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1785

Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases

Jazzia Emily Diaz-Angulo1, Cassandra M. Skinner-Taylor1, Lorena Perez-Barbosa1, Eugenio Salvador Barriga-Maldonado1, Marco Valdovinos2, Rita Pineda-Sic1, Jesus Alberto Cardenas-de la Garza1, Gabriel Figueroa-Parra3, Janett Carmen Riega-Torres4 and Dionicio Ángel Galarza-Delgado5, 1Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México., Monterrey, Nuevo Leon, Mexico, 2Hospital Universitario José Eleuterio González, Monterrey, Nuevo Leon, Mexico, 3Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 4Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México., Monterrey NL, Nuevo Leon, Mexico, 5Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico

Meeting: ACR Convergence 2020

Keywords: pregnancy, rheumatoid arthritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: The importance of safe and effective contraception for women with rheumatic diseases has been increasing. Several studies have demonstrated that carefully planned pregnancies are related with better outcomes making the use of contraceptive methods (CM) more significant. The objective is to describe the use of methods of contraception among Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE).

Methods: A Cross-sectional study, where women aged 18-45 followed in our outpatient clinic of reproductive health, pregnancy and rheumatic diseases (CEER), at Monterrey, Mexico, were questioned about the use of CM. Sociodemographic data was collected from the medical record. CM were classified as Ineffective (10-25% pregnant each year), effective (6-9% pregnant each year) and highly effective (< 1% pregnant each year). Methotrexate, Mycophenolate, Cyclophosphamide, Thalidomide and Leflunomide were considered as teratogenic drugs. The statistical analysis was performed using SPSS 24.0. A p< 0.05 was taken to indicate statistical significance.

Results: A total of 91 patients were included, 35 (38.5%) SLE patients with a median age of 30 years (22-39) and 56 (61.5%) RA patients with a median age of 34.5 years (27.25-40). From the total population, 58 (63.7%) reported the use of teratogenic drugs, with a higher use in RA patients (p < .001). Socio-demographic characteristics are listed in Table 1.

Among the patients that had started sexual activity (SLE n=24, RA n=46), highly effective methods were the most frequent, used by a total of 39 (55.7%) women. The most common CM in RA was tubal ligation reported by 20 (43.5%) patients, nevertheless 9 (37.5%) SLE patients mentioned that they did not used any method. Graphs 1.

From the group who started sexual activity, 49 (70%) patients received contraceptive counseling, however, 21 (42%) patients were using ineffective CM. Table 2.

Conclusion: Only 70% of the women with rheumatic diseases received a contraceptive counseling and despite this 42% continued using an ineffective method. It is necessary to promote the counseling and use of contraception and provide a multidisciplinary support among this high-risk population.

Table 1.Socio-demographic characteristics. RA: Rheumatoid Arthritis; SLE: Systemic Lupus Erythematosus. *Sexual activity in the last month.

Table 2. Methods according to effectiveness in patients who received contraception counseling. RA: Rheumatoid Arthritis; SLE: Systemic Lupus Erythematosus. * Total of patients that have started sexual activity.

Graphs 1. Use of contraceptive methods among patients who had started sexual activity. This graphic shows the percentage (%) of contraceptive methods used by Rheumatoid Arthritis (RA) n= 46 and Systemic Lupus Erythematosus (SLE) n=24 patients, which are categorized by the grade of effectiveness. IUD: Intrauterine Device. Only were included patients that had started sexual activity.


Disclosure: J. Diaz-Angulo, None; C. Skinner-Taylor, None; L. Perez-Barbosa, None; E. Barriga-Maldonado, None; M. Valdovinos, None; R. Pineda-Sic, None; J. Cardenas-de la Garza, None; G. Figueroa-Parra, None; J. Riega-Torres, None; D. Galarza-Delgado, None.

To cite this abstract in AMA style:

Diaz-Angulo J, Skinner-Taylor C, Perez-Barbosa L, Barriga-Maldonado E, Valdovinos M, Pineda-Sic R, Cardenas-de la Garza J, Figueroa-Parra G, Riega-Torres J, Galarza-Delgado D. Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/use-of-contraceptive-methods-in-mexican-women-with-rheumatic-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-contraceptive-methods-in-mexican-women-with-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology